Hemodynamic and pharmacokinetic analysis of oxymetazoline use during nasal surgery in children.


Journal

The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378

Informations de publication

Date de publication:
12 2019
Historique:
received: 17 07 2018
revised: 10 11 2018
accepted: 26 11 2018
pubmed: 21 2 2019
medline: 31 1 2020
entrez: 21 2 2019
Statut: ppublish

Résumé

Oxymetazoline is an α-adrenergic agonist that is commonly used as a topical hemostatic agent in the operating room during ear, nose, and throat surgery. There are limited data on oxymetazoline pharmacokinetics in children who undergo general anesthesia. We assessed the hemodynamic effects and systemic absorption of topically applied oxymetazoline in children undergoing various nasal procedures. Prospective trial. Children ages 2 to 17 years undergoing functional endoscopic sinus surgery, turbinate resection, or adenoidectomy were enrolled. The surgeon placed oxymetazoline-soaked pledgets (1.5 mL of 0.05% solution) according to our usual clinical practice. Blood samples for oxymetazoline assay were drawn at 5, 10, 20, 45, 90, and 150 minutes, and hemodynamic data were recorded at 5-minute intervals. Data analysis included mixed-effects regression and population pharmacokinetic/pharmacodynamic modeling. The analysis included 27 patients, age 7 ± 4 years, who received between 2 and 12 pledgets (3-18 mL) of oxymetazoline. Relative bioavailability compared to the spray formulation was 2.3 (95% confidence interval [CI]: 1.6-3.2), with slow absorption from the mucosal surface (absorption half-life 64 minutes; 95% CI: 44-90). Mean arterial pressure did not increase with oxymetazoline instillation at the observed oxymetazoline serum concentrations (0.04-7.6 μg/L). Despite concerns regarding oxymetazoline administration to mucosal membranes, we found that hemodynamic changes were clinically negligible with our usual clinical use of pledgets soaked in oxymetazoline. Compared to data on oxymetazoline in spray formulation, bioavailability was increased twofold with pledgets, but systemic absorption was very slow, contributing to low serum concentrations and limited hemodynamic effects. 1b. Laryngoscope, 129:2775-2781, 2019.

Identifiants

pubmed: 30786035
doi: 10.1002/lary.27760
pmc: PMC6702099
mid: NIHMS1031258
doi:

Substances chimiques

Adrenergic alpha-Agonists 0
Oxymetazoline 8VLN5B44ZY

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2775-2781

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001070
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002733
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1TR001070
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 The American Laryngological, Rhinological and Otological Society, Inc.

Références

Pediatr Emerg Care. 1989 Jun;5(2):110-2
pubmed: 2748403
Annu Rev Pharmacol Toxicol. 2008;48:303-32
pubmed: 17914927
Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76
pubmed: 15286277
Lancet. 2011 Mar 19;377(9770):1011-8
pubmed: 21411136
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):405-16
pubmed: 15000422
J Clin Pharmacol. 2017 Feb;57(2):247-254
pubmed: 27436060
Clin Pharmacokinet. 1996 May;30(5):329-32
pubmed: 8743333
Paediatr Anaesth. 2013 Oct;23(10):952-6
pubmed: 23679077
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):387-404
pubmed: 15000421
Paediatr Anaesth. 2002 Mar;12(3):205-19
pubmed: 11903934
J Pediatr Pharmacol Ther. 2016 May-Jun;21(3):247-51
pubmed: 27453703
J Am Dent Assoc. 2012 Aug;143(8):872-80
pubmed: 22855901
Eur J Pediatr. 1993 Nov;152(11):944-6
pubmed: 8276031
Laryngoscope. 1992 Jul;102(7):820-3
pubmed: 1614253
Fundam Clin Pharmacol. 2010 Dec;24(6):729-39
pubmed: 20030735
Ann Emerg Med. 1991 Jun;20(6):655-8
pubmed: 2039105
Otolaryngol Head Neck Surg. 2004 Nov;131(5):601-5
pubmed: 15523433
Cardiol Young. 2009 Dec;19(6):633-4
pubmed: 19775485

Auteurs

Richard S Cartabuke (RS)

Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio, U.S.A.
Department of Anesthesiology and Pain Medicine, The Ohio State University, Columbus, Ohio, U.S.A.

Brian J Anderson (BJ)

Department of Anesthesiology, University of Auckland, Auckland, New Zealand.

Charles Elmaraghy (C)

Department of Otolaryngology and Head and Neck Surgery, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio, U.S.A.

Julie Rice (J)

Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio, U.S.A.

Dmitry Tumin (D)

Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio, U.S.A.
Department of Anesthesiology and Pain Medicine, The Ohio State University, Columbus, Ohio, U.S.A.

Joseph D Tobias (JD)

Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio, U.S.A.
Department of Anesthesiology and Pain Medicine, The Ohio State University, Columbus, Ohio, U.S.A.
Department of Pediatrics, The Ohio State University, Columbus, Ohio, U.S.A.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH